Report
Iovance stock surges as strong melanoma drug demand drives growth
Barron's reports that Iovance Biotherapeutics raised its fiscal-year guidance on September 29.
TLDR
Barron's reports that Iovance stock surged as strong melanoma drug demand drove growth. The company also raised its fiscal-year guidance on September 29.
Combined views
4.5K
1 Source, first seen 4h ago
2 likes